Everyone Says Stop Your GLP-1 Before Surgery. A 10-Year Study Disagrees.

Everyone Says Stop Your GLP-1 Before Surgery. A 10-Year Study Disagrees.

The standard advice when you're heading into surgery on a GLP-1 like semaglutide or tirzepatide? Stop the drug. Clear the system. Come back to it later.

Most surgical teams tell patients this without hesitation. But a 10-year retrospective analysis of real patients undergoing abdominal panniculectomy just threw a wrench in that blanket recommendation — and the findings are worth understanding before you or someone you care about goes under the knife.

Important: I'm not a doctor. Everything I share here is based on published research and analysis of the data. Talk to your surgeon and physician before making any changes to your medication regimen.

---

The Bottom Line

• The standard "stop your GLP-1 before surgery" rule is based on anesthesia aspiration concerns — but a 10-year retrospective study found no significant difference in major surgical complications between panniculectomy patients who continued GLP-1 receptor agonists perioperatively versus those who did not.
• The aspiration risk from GLP-1-related gastric slowing is real — but may be overstated for elective, non-emergency surgeries with proper preoperative fasting protocols.
• Patients who stayed on GLP-1s around surgery actually trended toward better metabolic profiles going in, which may offset some of the risks surgeons worry about.
• The conversation needs to be individualized — blanket stop orders may be doing some patients more harm than good by disrupting metabolic stability.
• Actionable takeaway: If you're on a GLP-1 and scheduled for surgery, this study is a legitimate reason to have a deeper conversation with your care team rather than accepting "just stop it" as the final word.

---

Why Surgeons Tell You to Stop GLP-1s in the First Place

The concern is not irrational. GLP-1 receptor agonists slow gastric emptying — that's part of how they reduce appetite and keep you feeling full longer.

For surgery, slow gastric emptying is a problem. Food or liquid sitting in the stomach when anesthesia is administered raises the risk of aspiration — meaning stomach contents enter the lungs. That can be life-threatening.

The American Society of Anesthesiologists (ASA) issued guidance in 2023 recommending that patients hold weekly GLP-1 injections for one full week prior to elective procedures. For daily doses, the hold period was 24 hours. This guidance was later updated in 2024 to acknowledge that the evidence base was still evolving and that decisions should be individualized.

The problem? That original guidance was largely based on the known pharmacology of GLP-1s — not robust surgical outcome data. Surgeons, trained to minimize risk, defaulted to the most conservative interpretation.

And that's exactly where the 10-year retrospective analysis steps in.

---

What the 10-Year Study Actually Found

The study — published on PubMed (PMID: 40875227) — looked at patients undergoing nonbariatric abdominal panniculectomy (that's the surgery to remove excess skin and fat from the abdomen, often after major weight loss) over a 10-year period.

Researchers compared patients who were on GLP-1 receptor agonists perioperatively — meaning around the time of surgery — against those who were not.

Here's what they found:

No statistically significant increase in major surgical complications in the GLP-1 group compared to the non-GLP-1 group.

That includes wound complications, infection rates, and serious adverse events. The dreaded aspiration events that drive the "stop your GLP-1" policy? Not meaningfully elevated in this real-world dataset.

Now, this is a retrospective study — meaning researchers looked backward at existing records rather than running a controlled experiment. That limits the conclusions we can draw. But 10 years of real patient data is not nothing. This is the kind of signal that should prompt a serious re-examination of blanket stop orders.

---

The Contrarian Case: Stopping Might Not Be the Safer Choice

Here's the part nobody's talking about loudly enough.

Abruptly stopping a GLP-1 before surgery doesn't just remove the aspiration risk. It also removes the metabolic benefits.

Patients on semaglutide or tirzepatide for obesity and metabolic disease are often managing blood sugar, insulin resistance, and systemic inflammation at the same time. These factors directly affect surgical outcomes.

Research on GLP-1s — including a 2026 review in The New England Journal of Medicine by Rosen and Ingelfinger — confirms that these drugs do far more than delay gastric emptying. They modulate inflammatory pathways, improve endothelial function, and support cardiovascular stability.

When you pull someone off their GLP-1 a week before a major procedure, you potentially destabilize all of that. Blood sugar may creep up. Inflammatory markers may tick higher. And the patient walks into the OR in a metabolically weaker state.

The question is no longer just "does the GLP-1 raise aspiration risk?" It's "does stopping the GLP-1 raise a different set of risks that we're not accounting for?"

The 10-year panniculectomy data suggests the answer might be yes.

---

Why Panniculectomy Is the Right Test Case

You might be thinking — why does this study focus specifically on abdominal panniculectomy? Why not just look at all surgeries?

It's actually a smart choice of population. Here's why.

Panniculectomy patients are disproportionately people who've lost significant weight — often with the help of GLP-1 medications. They're the exact patients most likely to be on semaglutide or tirzepatide going into this kind of procedure.

They're also undergoing an elective, scheduled surgery. That means proper fasting protocols were in place. The chaotic aspiration risk of emergency surgeries doesn't apply here.

And abdominal panniculectomy is known to carry a baseline risk profile: wound healing complications, infection, fluid accumulation (seroma). These are exactly the outcomes where metabolic health — blood sugar control, inflammation, circulation — matters enormously.

If GLP-1s were genuinely dangerous in the perioperative window, this population would show it clearly. Over 10 years, they didn't.

---

What About the Aspiration Risk? It's Real — But Context Matters

Let's be direct: the aspiration concern is not made up. Case reports of patients with full stomachs despite extended fasting while on GLP-1s exist. This is a documented pharmacological effect.

But there's a meaningful difference between:

1. A patient on high-dose semaglutide undergoing emergency surgery with no fasting window
2. A planned, elective procedure with a properly observed fasting protocol and a surgical team experienced with this population

The 10-year retrospective data suggests that in scenario 2, the risk may be manageable — and that the benefit of metabolic stability might actually tip the scales.

A 2026 comprehensive review of GLP-1 receptor agonists published in the NEJM reinforces that these drugs have complex, systemic effects that go well beyond their GI action. Managing perioperative risk means accounting for all of those effects — not just the one that scares anesthesiologists.

---

What This Means If You're Planning a Surgery on a GLP-1

This is not a green light to ignore your surgical team's recommendations.

It is a reason to have a more informed conversation.

If your surgeon or anesthesiologist gives you the blanket "stop your GLP-1 a week before" instruction, here are the questions worth asking:

• What specific risks are you most concerned about for my procedure? Aspiration risk varies by surgery type, duration, and anesthesia approach.
• Is there evidence for this stop window beyond the 2023 ASA guidance? The guidance has already been updated once to reflect evolving data.
• Can we discuss a modified fasting protocol instead of a medication hold, if stopping creates metabolic instability for me?
• Are you aware of the 2025 panniculectomy retrospective data? You can point them directly to PMID 40875227.

None of this is confrontational. It's exactly the kind of shared decision-making that good surgical care looks like.

---

The Bigger Picture: GLP-1 Research Is Moving Faster Than Clinical Protocols

This surgical outcomes study is a microcosm of a larger problem in medicine right now.

GLP-1 receptor agonists are being used by tens of millions of people. The research on their effects — in surgery, in kidney disease, in liver health, in brain health — is expanding rapidly. A 2026 retrospective cohort study even found potential signals for GLP-1s reducing dementia onset in type 2 diabetes patients.

Clinical protocols, hospital policies, and surgical checklists haven't caught up.

That gap creates real problems. Patients get advice based on a 2023 blanket policy that was already being updated. Surgeons apply a one-size rule to a highly variable population. And the data that challenges the consensus sits in PubMed, largely unread by the people who need it most.

The panniculectomy study isn't the final word. But it's a clear signal that the "just stop it" default needs a second look — backed by 10 years of actual patient outcomes.

---

FAQ

Should I stop semaglutide or tirzepatide before surgery?

Current guidance from most surgical anesthesia groups recommends stopping weekly GLP-1 injections one week before elective surgery. However, a 10-year retrospective study found no significant increase in surgical complications in patients who continued GLP-1s perioperatively for panniculectomy. Discuss your specific situation with your surgeon — the answer may not be the same for everyone.

Why do GLP-1 drugs create a surgery risk in the first place?

GLP-1 receptor agonists slow gastric emptying, which means food and liquid clear the stomach more slowly than normal. If the stomach isn't empty when anesthesia is given, there's a risk of aspiration — stomach contents entering the lungs. This is why fasting before surgery is critical, and why some providers want the drug cleared from the system first.

What is a panniculectomy and why is this study population relevant?

A panniculectomy is a surgical procedure to remove excess skin and fat from the lower abdomen — often performed after significant weight loss. These patients are frequently on GLP-1 medications, making them an ideal real-world population to study perioperative GLP-1 use. The study followed these patients over 10 years.

Does stopping a GLP-1 before surgery actually create new risks?

Possibly, yes. GLP-1s support blood sugar control, reduce inflammation, and stabilize cardiovascular function. Abruptly stopping them before surgery could temporarily destabilize metabolic health — which also affects surgical outcomes. The 10-year study raises the question of whether the risks of stopping have been underweighted in current protocols.

Is the "stop your GLP-1 before surgery" guidance permanent?

No. The American Society of Anesthesiologists already updated its 2023 guidance to emphasize individualized decision-making as evidence evolved. This is an active area of clinical debate, and the panniculectomy retrospective data is likely to inform future updates.

---

The Bottom Line (Revisited)

A 10-year dataset doesn't prove that staying on your GLP-1 through surgery is always safe. What it does prove is that the blanket "stop it" order isn't supported by outcome data — at least not for this surgery type in this population.

The smarter path forward is individualized decision-making: a real conversation between patient and surgical team, informed by data like this, rather than a one-line policy applied uniformly to millions of people whose metabolic health depends on these medications.

If you're scheduled for surgery and currently on a GLP-1, bring this study to your appointment. PMID 40875227. That's the starting point for a better conversation.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis — PubMed, 2025
2. GLP-1 Receptor Agonists — Rosen CJ, Ingelfinger JR — The New England Journal of Medicine, 2026
3. Target Trial Emulations for Tirzepatide, Semaglutide and SGLT2-Inhibitors for Dementia in Patients with Type 2 Diabetes — Diabetes Research and Clinical Practice, 2026
4. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists — ASA, 2023 (updated 2024)
5. Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits — Endocrine Practice, 2026